Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 3/2014

01.06.2014

Novel Approaches to Food Allergy

verfasst von: Yao-Hsu Yang, Bor-Luen Chiang

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Food allergies have increased in recent decades. However, they cannot be effectively treated by the current management, which is limited to the identification and avoidance of foods that induce allergies and to the use of medicines for symptoms relief. To meet the medical need of prevention and cure of food allergies, several therapeutic strategies are under investigation. Some newly developed biologics such as anti-IgE antibody and anti-interleukin (IL)-5 antibody directed against significant molecules in the allergic process have shown their potential for the treatment of food allergies. Allergen-specific immunotherapy is the therapy that induces immune tolerance and may reduce the need for conventional medication, severity of allergic symptoms and eliminate hypersensitivity. In this article, clinical studies of immunotherapy via subcutaneous, oral, sublingual, and epicutaneous routes are extensively reviewed for their safety and effectiveness on various food allergies. In addition, to reduce the risk of anaphylaxis and increase toleragenic immunity, many studies are focusing on the modification of traditional allergens used for immunotherapy. Moreover, a Chinese herbal formulation with potential anti-allergic effects is being evaluated for its efficacy in patients with peanut allergy. Although more studies are needed, accumulated data of current studies represent compelling evidence of curative effects of some strategies and give a hope that food allergies are likely to be successfully treated in the future.
Literatur
1.
2.
Zurück zum Zitat Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 125:1322–1326PubMedCrossRef Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA (2010) US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 125:1322–1326PubMedCrossRef
6.
Zurück zum Zitat Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ (2006) Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 18:751–760PubMedCrossRef Grimbaldeston MA, Metz M, Yu M, Tsai M, Galli SJ (2006) Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 18:751–760PubMedCrossRef
8.
Zurück zum Zitat Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122:1161–1165PubMedCentralPubMedCrossRef Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122:1161–1165PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Scheinfeld N (2005) Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 11:2PubMed Scheinfeld N (2005) Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 11:2PubMed
10.
Zurück zum Zitat Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986–993PubMedCrossRef Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986–993PubMedCrossRef
11.
Zurück zum Zitat Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL et al (2011) A phase II, randomized, double-blind, parallel group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127:1309–1310PubMedCrossRef Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL et al (2011) A phase II, randomized, double-blind, parallel group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127:1309–1310PubMedCrossRef
12.
Zurück zum Zitat Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW et al (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31:76–83PubMedCrossRef Rafi A, Do LT, Katz R, Sheinkopf LE, Simons CW et al (2010) Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 31:76–83PubMedCrossRef
13.
Zurück zum Zitat Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134–140PubMedCrossRef Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134–140PubMedCrossRef
14.
Zurück zum Zitat Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S et al (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 21:e160–e165PubMedCrossRef Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S et al (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 21:e160–e165PubMedCrossRef
15.
16.
Zurück zum Zitat Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115–119PubMedCrossRef Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE et al (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113:115–119PubMedCrossRef
17.
Zurück zum Zitat Straumann A, Conus S, Grzonka P, Kita H, Kephart G et al (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21–30PubMedCrossRef Straumann A, Conus S, Grzonka P, Kita H, Kephart G et al (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59:21–30PubMedCrossRef
20.
Zurück zum Zitat Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27PubMedCrossRef Akdis CA, Akdis M (2011) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127:18–27PubMedCrossRef
21.
Zurück zum Zitat Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256–262PubMedCrossRef Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY (1992) Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 90:256–262PubMedCrossRef
22.
Zurück zum Zitat Nelson HS, Lahr J, Rule R, Bock A, Leung D (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99:744–751PubMedCrossRef Nelson HS, Lahr J, Rule R, Bock A, Leung D (1997) Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99:744–751PubMedCrossRef
23.
Zurück zum Zitat Katelaris CH (2010) Food allergy and oral allergy or pollen-food syndrome. Curr Opin Allergy Clin Immunol 10:246–251PubMedCrossRef Katelaris CH (2010) Food allergy and oral allergy or pollen-food syndrome. Curr Opin Allergy Clin Immunol 10:246–251PubMedCrossRef
24.
Zurück zum Zitat Asero R (1998) Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 28:1368–1373PubMedCrossRef Asero R (1998) Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 28:1368–1373PubMedCrossRef
25.
Zurück zum Zitat Bucher X, Pichler WJ, Dahinden CA, Helbling A (2004) Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59:1272–1276PubMedCrossRef Bucher X, Pichler WJ, Dahinden CA, Helbling A (2004) Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59:1272–1276PubMedCrossRef
26.
Zurück zum Zitat Kulis M, Vickery BP, Burks AW (2011) Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol Res 49:216–226PubMedCrossRef Kulis M, Vickery BP, Burks AW (2011) Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol Res 49:216–226PubMedCrossRef
27.
Zurück zum Zitat Beyer K, Wahn U (2008) Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 8:553–556PubMedCrossRef Beyer K, Wahn U (2008) Oral immunotherapy for food allergy in children. Curr Opin Allergy Clin Immunol 8:553–556PubMedCrossRef
28.
Zurück zum Zitat Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122:1154–1160PubMedCentralPubMedCrossRef Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S et al (2008) A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 122:1154–1160PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A (2008) Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121:343–347PubMedCrossRef Longo G, Barbi E, Berti I, Meneghetti R, Pittalis A (2008) Specific oral tolerance induction in children with very severe cow's milk-induced reactions. J Allergy Clin Immunol 121:343–347PubMedCrossRef
30.
Zurück zum Zitat Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D (2010) Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 105:376–381PubMedCrossRef Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D (2010) Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol 105:376–381PubMedCrossRef
31.
Zurück zum Zitat Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199–205PubMedCrossRef Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L (2007) Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119:199–205PubMedCrossRef
32.
Zurück zum Zitat Vickery BP, Pons L, Kulis M, Steele P, Jones SM (2010) Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 105:444–450PubMedCentralPubMedCrossRef Vickery BP, Pons L, Kulis M, Steele P, Jones SM (2010) Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 105:444–450PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Clark AT, Islam S, King Y, Deighton J, Anagnostou K (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64:1218–1220PubMedCrossRef Clark AT, Islam S, King Y, Deighton J, Anagnostou K (2009) Successful oral tolerance induction in severe peanut allergy. Allergy 64:1218–1220PubMedCrossRef
34.
Zurück zum Zitat Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT et al (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124:292–300PubMedCentralPubMedCrossRef Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT et al (2009) Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124:292–300PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127:654–660PubMedCentralPubMedCrossRef Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A et al (2011) A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127:654–660PubMedCentralPubMedCrossRef
36.
37.
Zurück zum Zitat Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE et al (2009) Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64:876–883PubMedCrossRef Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE et al (2009) Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 64:876–883PubMedCrossRef
38.
Zurück zum Zitat Enrique E, Pineda F, Malek T, Bartra J, Basagana M et al (2005) Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116:1073–1079PubMedCrossRef Enrique E, Pineda F, Malek T, Bartra J, Basagana M et al (2005) Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 116:1073–1079PubMedCrossRef
39.
Zurück zum Zitat Kim EH, Bird JA, Kulis M, Laubach S, Pons L et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127:640–646PubMedCentralPubMedCrossRef Kim EH, Bird JA, Kulis M, Laubach S, Pons L et al (2011) Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 127:640–646PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C et al (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119:937–943PubMedCrossRef Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwolfer B, Schreiber C et al (2007) Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol 119:937–943PubMedCrossRef
41.
Zurück zum Zitat Senti G, von Moos S, Kundig TM (2011) Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 66:798–809PubMedCrossRef Senti G, von Moos S, Kundig TM (2011) Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 66:798–809PubMedCrossRef
43.
Zurück zum Zitat Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H et al (2010) Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125:1165–1167PubMedCrossRef Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H et al (2010) Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125:1165–1167PubMedCrossRef
44.
Zurück zum Zitat Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M et al (2006) Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5:5–14PubMedCrossRef Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M et al (2006) Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5:5–14PubMedCrossRef
45.
Zurück zum Zitat Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S et al (2008) Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 122:342–347PubMedCrossRef Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S et al (2008) Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 122:342–347PubMedCrossRef
46.
Zurück zum Zitat Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S et al (2008) Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 122:977–983PubMedCrossRef Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S et al (2008) Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 122:977–983PubMedCrossRef
47.
Zurück zum Zitat Kim JS, Nowak-Wegrzyn A, Sicherer SH, Noone S, Moshier EL et al (2011) Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 128:125–131PubMedCentralPubMedCrossRef Kim JS, Nowak-Wegrzyn A, Sicherer SH, Noone S, Moshier EL et al (2011) Dietary baked milk accelerates the resolution of cow's milk allergy in children. J Allergy Clin Immunol 128:125–131PubMedCentralPubMedCrossRef
48.
49.
Zurück zum Zitat Chuang YH, Yang YH, Wu SJ, Chiang BL (2009) Gene therapy for allergic diseases. Curr Gene Ther 9:185–191PubMedCrossRef Chuang YH, Yang YH, Wu SJ, Chiang BL (2009) Gene therapy for allergic diseases. Curr Gene Ther 9:185–191PubMedCrossRef
50.
Zurück zum Zitat Chua KY, Huangfu T, Liew LN (2006) DNA vaccines and allergic diseases. Clin Exp Pharmacol Physiol 33:546–550PubMedCrossRef Chua KY, Huangfu T, Liew LN (2006) DNA vaccines and allergic diseases. Clin Exp Pharmacol Physiol 33:546–550PubMedCrossRef
51.
Zurück zum Zitat Li XM, Srivastava K, Grishin A, Huang CK, Schofield B et al (2003) Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112:159–167PubMedCrossRef Li XM, Srivastava K, Grishin A, Huang CK, Schofield B et al (2003) Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112:159–167PubMedCrossRef
52.
Zurück zum Zitat DeLong JH, Simpson KH, Wambre E, James EA, Robinson D et al (2011) Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 127:1211–1218PubMedCentralPubMedCrossRef DeLong JH, Simpson KH, Wambre E, James EA, Robinson D et al (2011) Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 127:1211–1218PubMedCentralPubMedCrossRef
53.
Zurück zum Zitat Li X, Huang CK, Schofield BH, Burks AW, Bannon GA et al (1999) Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 162:3045–3052PubMed Li X, Huang CK, Schofield BH, Burks AW, Bannon GA et al (1999) Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 162:3045–3052PubMed
54.
Zurück zum Zitat Li XM, Zhang TF, Huang CK, Srivastava K, Teper AA et al (2001) Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 108:639–646PubMedCrossRef Li XM, Zhang TF, Huang CK, Srivastava K, Teper AA et al (2001) Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 108:639–646PubMedCrossRef
55.
Zurück zum Zitat Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L et al (2005) The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115:171–178PubMedCrossRef Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L et al (2005) The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115:171–178PubMedCrossRef
56.
Zurück zum Zitat Wang J, Patil SP, Yang N, Ko J, Lee J et al (2010) Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 105:75–84PubMedCentralPubMedCrossRef Wang J, Patil SP, Yang N, Ko J, Lee J et al (2010) Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 105:75–84PubMedCentralPubMedCrossRef
Metadaten
Titel
Novel Approaches to Food Allergy
verfasst von
Yao-Hsu Yang
Bor-Luen Chiang
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 3/2014
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-013-8354-2

Weitere Artikel der Ausgabe 3/2014

Clinical Reviews in Allergy & Immunology 3/2014 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.